Keywords
Mycophenolate mofetil
Cyclophosphamide
Lupus nephritis
Complete renal remission rate
Total renal remission rates
End Systemic Lupus Erythematosus Disease Activity Index
Proteinuria
Serum creatinine
Submitted : 2023-04-30
Accepted : 2023-05-15
Published : 2023-05-30
Abstract
Objective: To evaluate the effects of rituximab versus mycophenolate mofetil or cyclophosphamide as control in lupus nephritis by meta-analysis. Methods: A systematic search was carried out up to January 2022, obtaining 7 studies involving 645 participants with lupus nephritis at the commencement of the investigation; 198 of them were treated with rituximab, while 447 were treated with mycophenolate mofetil or cyclophosphamide. We determined the odds ratio (OR) and mean difference (MD) with 95% confidence index (CI) to compare rituximab’s efficacy to that of mycophenolate mofetil or cyclophosphamide as control in lupus nephritis using random- or fixed-effects model by dichotomous or continuous techniques. Results: The rituximab group showed significantly higher complete renal remission rate (OR = 2.52; 95% CI 1.30–4.91, P = 0.006) and total renal remission rates (OR = 2.22; 95% CI 1.36–3.63, P = 0.001) than the control group. However, there was no significant difference in terms of end Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score (MD -1.16; 95% CI -2.88–0.57, P = 0.19), proteinuria (MD -0.31; 95% CI -0.70–0.09, P = 0.013), and serum creatinine (MD 0.01; 95% CI -0.04–0.07, P = 0.64) between the rituximab group and the control. Conclusion: Rituximab exhibited significantly greater complete renal remission rate and total renal remission rates, with no significant difference in terms of shorter-end SLEDAI, proteinuria, and serum creatinine, compared with the control in individuals with lupus nephritis.
References
Anders H-J, Fogo AB, 2014, Immunopathology of Lupus Nephritis. Semin Immunopathol, 36(4): 443–459.
Moroni G, Raffiotta F, Trezzi B, et al., 2014, Rituximab vs Mycophenolate and Vs Cyclophosphamide Pulses for Induction Therapy of Active Lupus Nephritis: A Clinical Observational Study. Rheumatology, 53(9): 1570–1577.
Cheng Q, Mumtaz IM, Khodadadi L, et al., 2013, Autoantibodies from Long-Lived “Memory” Plasma Cells of NZB/W Mice Drive Immune Complex Nephritis. Ann Rheum Dis, 72(12): 2011–2017.
Reis J, Aguiar F, Brito I, 2016, Anti CD 20 (Rituximab) Therapy in Refractory Pediatric Rheumatic Diseases. Acta Reumatol Port, 41(1): 45–55.
Zhang J, Zhao Z, Hu X, 2015, Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis. Cell Biochem Biophys, 72(1): 197–201.
Moroni G, Gallelli B, Sinico RA, et al., 2012, Rituximab Versus Oral Cyclophosphamide for Treatment of Relapses of Proliferative Lupus Nephritis: A Clinical Observational Study. Ann Rheum Dis, 71(10): 1751–1752.
Allameh F, Sangian A, Razaghi M, et al., 2022, Comparison of Various Types of Lasers and Transurethral Resection in the Treatment of Bladder Tumors: A Systematic Review and Meta-Analysis. Lasers Med Sci, 37(1): 95–101.
Stroup DF, Berlin JA, Morton SC, et al., 2000, Meta-Analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA, 283(15): 2008–2012.
Liberati A, Altman DG, Tetzlaff J, et al., 2009, The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. J Clin Epidemiol, 62(10): e1–e34.
Gupta A, Das A, Majumder K, et al., 2018, Obesity Is Independently Associated with Increased Risk of Hepatocellular Cancer-Related Mortality. Am J Clin Oncol, 41(9): 874–881.
Higgins JP, Thompson SG, Deeks JJ, et al., 2003, Measuring Inconsistency in Meta-Analyses. BMJ, 327(7414): 557–560.
Rovin BH, Furie R, Latinis K, et al., 2012, Efficacy and Safety of Rituximab in Patients with Active Proliferative Lupus Nephritis: The Lupus Nephritis Assessment with Rituximab Study. Arthritis Rheum, 64(4): 1215–1226.
Goswami RP, Sircar G, Sit H, et al., 2019, Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study. J Clin Rheumatol, 25(1): 28–35.
Roccatello D, Sciascia S, Naretto C, et al., 2021, A Prospective Study on Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol Without Maintenance Therapy. Kidney Int Rep, 6(4): 1081–1087.
Gururani S, Devarasetti PK, Uppin M, et al., 2021, Treatment Outcomes in Refractory Lupus Nephritis: Data from an Observational Study. Lupus, 30(11): 1725–1731.
Kotagiri P, Martin A, Hughes P, et al., 2016, Single?Dose Rituximab in Refractory Lupus Nephritis. Intern Med J, 46(8): 899–901.
Iaccarino L, Bartoloni E, Carli L, et al., 2015, Efficacy and Safety of Off-Label Use of Rituximab in Refractory Lupus: Data from the Italian Multicentre Registry. Clin Exp Rheumatol, 33(4): 449–456.
Contis A, Vanquaethem H, Truchetet M-E, et al., 2016, Analysis of the Effectiveness and Safety of Rituximab in Patients with Refractory Lupus Nephritis: A Chart Review. Clin Rheumatol, 35(2): 517–522.
Li C, Gao L, Zhang J, et al., 2020, The Effect of Holmium Laser Resection Versus Standard Transurethral Resection on Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Lasers Med Sci, 35(5): 1025–1034.
Goonewardene SS, Persad R, Motiwala H, et al., 2020, Systematic Review – Results from En-Bloc Resection of Bladder Cancer, in Management of Non-Muscle Invasive Bladder Cancer, Springer Nature, Berlin, 129–139.
Xu J, Wang C, Ouyang J, et al., 2020, Efficacy and Safety of Transurethral Laser Surgery Versus Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A Meta-Analysis and Systematic Review. Urol Int, 104(9–10): 810–823.
Long G, Zhang Y, Sun G, et al., 2021, Safety and Efficacy of Thulium Laser Resection of Bladder Tumors Versus Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis. Lasers Med Sci, 36(9): 1807–1816.